Acadia Pharmaceuticals Inc [NASDAQ: ACAD] traded at a low on Thursday, posting a -11.21 loss after which it closed the day’ session at $15.21.
The results of the trading session contributed to over 5276519 shares changing hands. Over the past one week, the price volatility of Acadia Pharmaceuticals Inc stands at 5.44% while the volatility over the past one month is 3.74%.
The market cap for ACAD stock reached $2.51 billion, with 164.65 million shares outstanding and 163.89 million shares in the current float. Compared to the average trading volume of 1.84M shares, ACAD reached a trading volume of 5276519 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Acadia Pharmaceuticals Inc [ACAD]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ACAD shares is $27.48 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ACAD stock is a recommendation set at 1.71. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Needham have made an estimate for Acadia Pharmaceuticals Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on March 12, 2024. While these analysts kept the previous recommendation, Mizuho dropped their target price from $39 to $25. The new note on the price target was released on March 12, 2024, representing the official price target for Acadia Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $40, while Robert W. Baird analysts kept a Outperform rating on ACAD stock.
The Average True Range (ATR) for Acadia Pharmaceuticals Inc is set at 0.72, with the Price to Sales ratio for ACAD stock in the period of the last 12 months amounting to 3.09. The Price to Book ratio for the last quarter was 5.41, with the Price to Cash per share for the same quarter was set at 2.85. Price to Free Cash Flow for ACAD in the course of the last twelve months was 39.47 with Quick ratio for the last quarter at 1.86.
How has ACAD stock performed recently?
Acadia Pharmaceuticals Inc [ACAD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -10.95. With this latest performance, ACAD shares dropped by -14.21% in over the last four-week period, additionally sinking by -35.28% over the last 6 months – not to mention a drop of -29.02% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACAD stock in for the last two-week period is set at 26.90, with the RSI for the last a single of trading hit 23.12, and the three-weeks RSI is set at 29.15 for Acadia Pharmaceuticals Inc [ACAD]. The present Moving Average for the last 50 days of trading for this stock 18.59, while it was recorded at 16.73 for the last single week of trading, and 23.88 for the last 200 days.
Acadia Pharmaceuticals Inc [ACAD]: Deeper insight into the fundamentals
Acadia Pharmaceuticals Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.86 and a Current Ratio set at 2.04.
Insider trade positions for Acadia Pharmaceuticals Inc [ACAD]
The top three institutional holders of ACAD stocks are: VANGUARD GROUP INC with ownership of 1.32 billion shares, which is approximately 8.4983%. BLACKROCK INC., holding 1.04 billion shares of the stock with an approximate value of $200.69 billion in ACAD stocks shares; and BERKSHIRE HATHAWAY INC, currently with $174.35 billion in ACAD stock with ownership which is approximately 5.8386%.
